Purpose: To determine whether SIRT1 regulates high glucose (HG)–induced inflammation and cataract formation through modulating TXNIP/NLRP3 inflammasome activation in human lens epithelial cells (HLECs) and rat lenses. Methods: HG stress from 25 to 150 mM was imposed on HLECs, with treatments using small interfering RNAs (siRNAs) targeting NLRP3, TXNIP, and SIRT1, as well as a lentiviral vector (LV) for SIRT1. Rat lenses were cultivated with HG media, with or without the addition of NLRP3 inhibitor MCC950 or SIRT1 agonist SRT1720. High mannitol groups were applied as the osmotic controls. Real-time PCR, Western blots, and immunofluorescent staining evaluated the mRNA and protein levels of SIRT1, TXNIP, NLRP3, ASC, and IL-1β. Reactive oxygen species (ROS) generation, cell viability, and death were also assessed. Results: HG stress induced a decline in SIRT1 expression and caused TXNIP/NLRP3 inflammasome activation in a concentration-dependent manner in HLECs, which was not observed in the high mannitol–treated groups. Knocking down NLRP3 or TXNIP inhibited NLRP3 inflammasome-induced IL-1β p17 secretion under HG stress. Transfections of si-SIRT1 and LV-SIRT1 exerted inverse effects on NLRP3 inflammasome activation, suggesting that SIRT1 acts as an upstream regulator of TXNIP/NLRP3 activity. HG stress induced lens opacity and cataract formation in cultivated rat lenses, which was prevented by MCC950 or SRT1720 treatment, with concomitant reductions in ROS production and TXNIP/NLRP3/IL-1β expression levels. Conclusions: The TXNIP/NLRP3 inflammasome pathway promotes HG-induced inflammation and HLEC pyroptosis, which is negatively regulated by SIRT1. This suggests viable strategies for treating diabetic cataract.
Introduction To evaluate and characterize adverse events (AEs) associated with EVO and EVO+ implantable collamer lens (ICL) using real-world post-marketing surveillance data from the Food and Drug Administration (FDA)'s MAUDE database. Methods A retrospective analysis was conducted on AE reports related to EVO and EVO+ ICLs, including both spherical and toric models, submitted between 2015 and 2023. After excluding duplicate entries and incomplete records, reports were stratified by lens model and optical type into four groups: spherical EVO, toric EVO, spherical EVO+, and toric EVO+. Each report was independently reviewed by two senior ophthalmologists to classify the associated complications. Descriptive statistics were used to evaluate the proportional distribution of complications across subgroups and to assess the annual trend in reported AEs. Results A total of 17,482 AEs reports were analyzed. Across all subgroups, over half of the reports documented no clinical signs or symptoms. Blurred vision was the most frequently reported visual complaint, with a relatively higher reporting frequency in the EVO+ groups. Events involving elevated intraocular pressure and glaucoma were more commonly reported among EVO+ recipients. In addition, a number of rare but clinically significant complications were documented, including hemorrhage, hyphema, decreased intraocular pressure, endophthalmitis, and toxic anterior segment syndrome. The annual number of reported AEs showed a consistent upward trend throughout the study period. Conclusion This real-world data analysis provides insights into the distribution of major complications associated with ICL implantation in clinical practice. Comprehensive identification and reporting of rare adverse outcomes may help surgeons broaden their perspectives, enhance surgical preparedness, and provide more personalized and informed preoperative counseling.
2 February 2026 in Investigative Ophthalmology & Visual Science
As a multifactorial ocular surface pathology, dry eye (DE) is marked by inflammation and epithelial damage. While mitochondrial dysfunction and oxidative stress are implicated, the mechanisms driving cornea epithelial cell damage remain unclear. This study investigates the role of C5a-mitochondrial C5a receptor 1 (mtC5aR1) in human corneal epithelial cells (HCECs) during DE pathogenesis. We examined C5aR1 expression and localization in HCECs under normal and hyperosmotic stress (mimicking DE) using molecular techniques. The functional role of the intracellular C5a-mtC5aR1 axis was assessed through pharmacological inhibition (JPE-1375 and PMX-53) and analysis of downstream signaling (RIPK3/MLKL-mediated necroptosis, DRP1 activation, mitochondrial function, and inflammatory cytokine production). The therapeutic potential of JPE-1375 was further evaluated in a DE mouse model, assessing corneal epithelial damage and inflammation. We demonstrate, for the first time, that HCECs express C5aR1 on the outer mitochondrial membrane (mtC5aR1), and its expression is upregulated in DE conditions. Hyperosmotic stress-induced local C5a production in HCECs activates mtC5aR1, triggering DRP1-mediated mitochondrial dysfunction and initiating RIPK3/MLKL-dependent necroptosis. Pharmacological blockade of mtC5aR1 with JPE-1375 significantly attenuated necroptosis, restored mitochondrial function, and reduced inflammatory cytokine production in stressed HCECs. Furthermore, JPE-1375 treatment mitigated corneal epithelial damage and inflammation in the DE mouse model. Our findings identify the intracellular C5a-mtC5aR1-DRP1 axis as a novel regulatory mechanism driving necroptosis in DE. Targeting this pathway represents a potential therapeutic approach to reduce inflammation and corneal damage in DE.